Publication Date
7-26-2022
Journal
World Journal of Cardiology
DOI
10.4330/wjc.v14.i7.392
PMID
36161057
PMCID
PMC9350602
PubMedCentral® Posted Date
7-26-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
COVID-19, Coronavirus, Cardiomyopathy, Heart failure, Cardiomyopathy
Abstract
Coronavirus disease 2019 (COVID-19) is primarily an infection of the respiratory tract, but it can have multisystem manifestations. Cardiac complications of COVID-19 can range from acute myocardial injury, cardiac arrhythmias, or heart failure, amongst others. Heart failure (HF) in COVID-19 can be a de novo process or due to worsening of pre-existing cardiovascular ailment. HF in a patient with COVID-19 not only poses challenges in clinical presentation and management of COVID-19 but also affect prognosis of the patient. This article aims to succinctly revisit the implications of this pandemic regarding pre-existing HF or new-onset HF based on prevailing data. It also focuses on the management and special recommendations from prior studies and guidelines.
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Cardiology Commons, Cardiovascular Diseases Commons, Community Health and Preventive Medicine Commons, COVID-19 Commons, Health Services Administration Commons, Medical Sciences Commons, Respiratory Tract Diseases Commons